About the Company
Amphastar Pharmaceuticals is a publicly traded American speciality pharmaceutical company. It was incorporated in May 2004 and primarily develops, manufactures, and sells inhalation and intranasal products.One of its products is naloxone, an injectable generic drug that treats opioid overdose, and the company was criticized when it doubled the price of the drug from around $20 to $40 in 2015 during the opioid epidemic. In February 2017, the FDA rejected the company's application to market a device that delivers naloxone intranasally.In March 2018, the company won a patent infringement lawsuit brought against it by Momenta Pharmaceuticals and Sandoz Inc in an ongoing antitrust case.In April 2023, Amphastar Pharmaceuticals bought Baqsimi from Eli Lilly in a deal worth over $1bn.
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $AMPH News
Amphastar Pharmaceuticals Poised for Growth: Strong Generic Pipeline and Strategic Marketing Drive Buy Rating
Analyst Tim Chiang of Capital One Financial maintained a Buy rating on Amphastar Pharmaceuticals (AMPH – Research Report), retaining the ...
Amphastar Pharmaceuticals Interested In Potential Acquisitions In Endocrinology-Focused Companies
Amphastar Pharmaceuticals discusses the future of Baqsimi at the Needham Healthcare Conference, highlighting its potential ...
Amphastar Pharmaceuticals Inc AMPH
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Amphastar: Q4 Earnings Snapshot
RANCHO CUCAMONGA, Calif. (AP) — RANCHO CUCAMONGA, Calif. (AP) — Amphastar Pharmaceuticals Inc. (AMPH) on Wednesday reported fourth-quarter earnings of $36.2 million. On a per-share basis ...
Amphastar Pharma Stock (NASDAQ:AMPH), Quotes and News Summary
Amphastar Pharmaceuticals Interested In Potential ... "Mad Money Lightning Round," Jim Cramer said he would back Moderna, Inc. (NASDAQ: MRNA) here.
Amphastar Pharmaceuticals, Inc. (AMPH)
Amphastar Pharmaceuticals, Inc. ( NASDAQ:AMPH ) shareholders might be concerned after seeing the share price drop 26... The latest trading day saw Amphastar Pharmaceuticals (AMPH) settling at $41. ...
Amphastar Pharmaceuticals Inc.
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
Loading the latest forecasts...